Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Colorectal Neoplasms

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 87 articles: HTML format

Single Articles

March 2026
1. VAN MEGESEN K, Stefan A, Kieboom M, Amico R, et al
   Targeting the DNA damage response prevents regrowth of colorectal peritoneal metastasis-derived organoids following treatment with mitomycin C.
   Br J Cancer. 2026;134:831-842.
   PubMed     Abstract available
   
   
   
2. JIANG H, Livingston M, Room R, Kibret AA, et al
   Alcohol consumption and mortality from four alcohol-related cancers in Australia 1950-2018: a time series analysis.
   Br J Cancer. 2026;134:914-923.
   PubMed     Abstract available
   
   
   February 2026
3. REE AH, Bousquet PA, Visnovska T, Luders T, et al
   Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.
   Br J Cancer. 2026 Feb 23. doi: 10.1038/s41416-026-03357.
   PubMed     Abstract available
   
   
   
4. AIJALA VK, Harkonen J, Sirnio P, Mantere T, et al
   Urothelium marker UPK2 identifies aggressive colorectal cancers with distinct molecular and histological features.
   Br J Cancer. 2026;134:650-661.
   PubMed     Abstract available
   
   
   
5. SOLE L, Canton E, Maqueda M, Lobo-Jarne T, et al
   ColoStem, a core oncofetal signature that identifies poor prognosis colorectal tumors.
   Br J Cancer. 2026;134:638-649.
   PubMed     Abstract available
   
   
   January 2026
6. RONG Z, Xing J, Wu L, Zheng K, et al
   ULK1 promotes oxaliplatin resistance of colon cancer via phosphorylation of Bax S184.
   Br J Cancer. 2026 Jan 13. doi: 10.1038/s41416-025-03223.
   PubMed     Abstract available
   
   
   
7. GWENZI T, Weber ANR, Trares K, Vlaski T, et al
   Effects of personalized vitamin D(3) on inflammation in colorectal cancer patients: a randomized trial.
   Br J Cancer. 2026 Jan 8. doi: 10.1038/s41416-025-03333.
   PubMed     Abstract available
   
   
   
8. ZHANG X, Jin M, Chu Y, Liu F, et al
   STK32C activated IL-6/JAK2/STAT3 signaling and promoted tumor angiogenesis.
   Br J Cancer. 2026;134:60-71.
   PubMed     Abstract available
   
   
   
9. BOWDEN SJ, Ellis LB, Cuming T, Brogden D, et al
   Multizonal intraepithelial neoplasia of the lower genital tract and anus in women: terminology for defining the disease, an introduction by the British Society for Colposcopy and Cervical Pathology (BSCCP), International Anal Neoplasia Society (IANS),
   Br J Cancer. 2026;134:177-184.
   PubMed     Abstract available
   
   
   December 2025
10. LASKAR RS, Murphy N, Ferrari P, Brennan P, et al
    A prospective investigation of early-onset colorectal cancer risk factors-pooled analysis of three large-scale European cohorts.
    Br J Cancer. 2025 Dec 20. doi: 10.1038/s41416-025-03303.
    PubMed     Abstract available
    
    
    
11. DENG JW, Zhou YL, Zhang YX, Zhou CB, et al
    The relationship between gut microbiota, lifestyle habits, and early-onset colorectal cancer: shedding light on early prediction.
    Br J Cancer. 2025 Dec 9. doi: 10.1038/s41416-025-03277.
    PubMed     Abstract available
    
    
    
12. MATSUBARA Y, Bando H, Nakamura Y, Misumi T, et al
    Survival outcomes of ERBB2-amplified metastatic colorectal cancer treated with first-line chemotherapy.
    Br J Cancer. 2025 Dec 8. doi: 10.1038/s41416-025-03270.
    PubMed     Abstract available
    
    
    
13. LEE HJ, Lee JH, Kang J, Kim K, et al
    Single-cell multiomic modelling of early metastatic events promoted by the extracellular matrix.
    Br J Cancer. 2025;133:1708-1719.
    PubMed     Abstract available
    
    
    November 2025
14. SKARIN NORDENVALL A, Persson F, Martling A, Nordenskjold M, et al
    Risk of malignant melanoma and colorectal cancer in Birt-Hogg-Dube syndrome - a matched cohort study.
    Br J Cancer. 2025 Nov 5. doi: 10.1038/s41416-025-03258.
    PubMed     Abstract available
    
    
    October 2025
15. OSTERMAN E, Syriopoulou E, Martling A, Andersson TM, et al
    Impact of socioeconomics on recurrences and survival in non-metastasized colorectal cancer.
    Br J Cancer. 2025 Oct 4. doi: 10.1038/s41416-025-03224.
    PubMed     Abstract available
    
    
    
16. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
    Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
    Br J Cancer. 2025;133:874-885.
    PubMed     Abstract available
    
    
    
17. THONG MSY, Doege D, Koch-Gallenkamp L, Bertram H, et al
    Fatigue in long-term cancer survivors: prevalence, associated factors, and mortality. A prospective population-based study.
    Br J Cancer. 2025;133:831-843.
    PubMed     Abstract available
    
    
    
18. YU H, Jin S, Zeng M, Yang Z, et al
    TIGIT antibody with PVR competitive ability enhances cancer immunotherapy and capable of eliciting anti-tumour immune memory.
    Br J Cancer. 2025;133:743-755.
    PubMed     Abstract available
    
    
    
19. HOPPENER DJ, Verheul SML, Nierop PMH, Buisman FE, et al
    The colorectal liver metastasis growth pattern phenotype is not dependent on genotype.
    Br J Cancer. 2025;133:945-955.
    PubMed     Abstract available
    
    
    September 2025
20. XIE W, Luo Q, Ou Z, Liu W, et al
    An ABCC1-based risk model is effective in the diagnosis of synchronous peritoneal metastasis in advanced colorectal cancer.
    Br J Cancer. 2025 Sep 26. doi: 10.1038/s41416-025-03203.
    PubMed     Abstract available
    
    
    
21. KAWAMURA H, Honda M, Nakayama Y, Oba K, et al
    Adverse events of postoperative adjuvant chemotherapy predict survival outcomes in locally advanced colorectal cancer: a pooled analysis of Japanese clinical trials.
    Br J Cancer. 2025 Sep 22. doi: 10.1038/s41416-025-03199.
    PubMed     Abstract available
    
    
    
22. FENG Y, Zhu J, Ou C, Deng Z, et al
    Retraction Note: MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1.
    Br J Cancer. 2025 Sep 19. doi: 10.1038/s41416-025-03209.
    PubMed    
    
    
    
23. MONTERO-CALLE A, Jimenez de Ocana S, Rejas-Gonzalez R, Benavente-Naranjo R, et al
    Deciphering the central role of TMOD2 in colorectal cancer progression and metastasis.
    Br J Cancer. 2025 Sep 17. doi: 10.1038/s41416-025-03184.
    PubMed     Abstract available
    
    
    August 2025
24. BALLHAUSEN A, Morano F, Stahler A, Lonardi S, et al
    Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials.
    Br J Cancer. 2025 Aug 28. doi: 10.1038/s41416-025-03164.
    PubMed     Abstract available
    
    
    
25. BARLOW M, Messenger D, Preece R, Prowse A, et al
    The diagnostic accuracy of the faecal immunochemical test for the detection of early-onset colorectal cancer: an age-stratified analysis in South West England.
    Br J Cancer. 2025 Aug 22. doi: 10.1038/s41416-025-03154.
    PubMed     Abstract available
    
    
    
26. ZHANG D, Yang S, Xu H, Chen Z, et al
    The novel role of DUSP4 in suppressing ferroptosis and promoting cytotoxicity of CD8(+) T cells in MSI colorectal cancer.
    Br J Cancer. 2025 Aug 22. doi: 10.1038/s41416-025-03119.
    PubMed     Abstract available
    
    
    
27. GALMARINI CM, Zamora R, Gomez Del Campo P, Del Castillo-Izquierdo J, et al
    PROCC: a predictive score to identify KRAS wild type metastatic colorectal cancer patients who are likely to obtain survival benefit from panitumumab treatment.
    Br J Cancer. 2025 Aug 20. doi: 10.1038/s41416-025-03157.
    PubMed     Abstract available
    
    
    
28. TOH Y, Wu L, Tu J, Liang Z, et al
    Anti-tumor activity of camptothecin analog conjugate of an RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancer.
    Br J Cancer. 2025 Aug 18. doi: 10.1038/s41416-025-03121.
    PubMed     Abstract available
    
    
    July 2025
29. SHENG Y, Yan L, Liu Q, Peng Y, et al
    The pronounced cytotoxic effects of chimeric antigen receptor T cells targeting B7-H3 in organoids and liver xenografts derived from colorectal cancer patients.
    Br J Cancer. 2025 Jul 28. doi: 10.1038/s41416-025-03114.
    PubMed     Abstract available
    
    
    
30. YU L, Guo Q, Gu X, Wang Z, et al
    Impact of gut microbiome on radiotherapy and immunotherapy efficacy in microsatellite-stable colorectal cancer: role of propionic acid and B. fragilis.
    Br J Cancer. 2025 Jul 26. doi: 10.1038/s41416-025-03105.
    PubMed     Abstract available
    
    
    
31. ZHANG J, Xiao Z, Lai D, Sun J, et al
    Retraction Note: miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
    Br J Cancer. 2025 Jul 25. doi: 10.1038/s41416-025-03135.
    PubMed    
    
    
    
32. ZHANG J, Dong H, Liang L, Hu L, et al
    Targeting gut microbiota and arginase boosts MEK inhibitors' enhancement of antitumour immunity via MHC-I upregulation in colorectal cancer.
    Br J Cancer. 2025 Jul 17. doi: 10.1038/s41416-025-03106.
    PubMed     Abstract available
    
    
    
33. SEO JW, Kim JY, Ha YJ, Tak KH, et al
    Prognostic and therapeutic value of a 23-gene risk score tailored to the molecular characteristics of mucinous colorectal cancer.
    Br J Cancer. 2025 Jul 2. doi: 10.1038/s41416-025-03104.
    PubMed     Abstract available
    
    
    June 2025
34. MESA-EGUIAGARAY I, Iakovliev A, Li X, Timofeeva M, et al
    Association between methylation quantitative trait loci and colorectal cancer risk, survival and cancer recurrence.
    Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03064.
    PubMed     Abstract available
    
    
    
35. ZHONG W, Zhang Y, Wang W, Shao Z, et al
    TRIM26 deficiency potentially suppresses colorectal cancer liver metastasis through NF-kappaB-mediated M1-like tumor-associated macrophage polarization.
    Br J Cancer. 2025 Jun 9. doi: 10.1038/s41416-025-03072.
    PubMed     Abstract available
    
    
    
36. RUBIO-CUESTA B, Carretero-Puche C, Llamas P, Sarmentero J, et al
    Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer.
    Br J Cancer. 2025 Jun 6. doi: 10.1038/s41416-025-03058.
    PubMed     Abstract available
    
    
    
37. ANDEL D, Nouwens AJ, Klaassen S, Laoukili J, et al
    Rational design of alternative treatment options for radioresistant rectal cancer using patient-derived organoids.
    Br J Cancer. 2025;132:973-981.
    PubMed     Abstract available
    
    
    April 2025
38. YUAN F, Jia G, Wen W, Xu S, et al
    Blood metabolic biomarkers and colorectal cancer risk: results from large prospective cohort and Mendelian randomisation analyses.
    Br J Cancer. 2025 Apr 30. doi: 10.1038/s41416-025-02997.
    PubMed     Abstract available
    
    
    
39. REITSAM NG, Markl B
    Stroma AReactive Invasion Front Areas (SARIFA) and the tumour immune microenvironment in colorectal cancer.
    Br J Cancer. 2025 Apr 26. doi: 10.1038/s41416-025-03034.
    PubMed    
    
    
    
40. LEE HJ, Park SW, Lee JH, Chang SY, et al
    Correction: Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes.
    Br J Cancer. 2025 Apr 11. doi: 10.1038/s41416-025-02988.
    PubMed    
    
    
    
41. HASJIM BJ, Ostowari A, Gandawidjaja M, Mohammadi MD, et al
    De novo colorectal cancer after kidney transplantation: a systematic review and meta-analysis.
    Br J Cancer. 2025 Apr 5. doi: 10.1038/s41416-025-02994.
    PubMed     Abstract available
    
    
    
42. ELOMAA H, Tarkiainen V, Aijala VK, Sirnio P, et al
    Associations of mucinous differentiation and mucin expression with immune cell infiltration and prognosis in colorectal adenocarcinoma.
    Br J Cancer. 2025;132:660-669.
    PubMed     Abstract available
    
    
    March 2025
43. GRANCHER A, Beaussire-Trouvay L, Vernon V, Dutherage M, et al
    ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer.
    Br J Cancer. 2025 Mar 15. doi: 10.1038/s41416-025-02971.
    PubMed     Abstract available
    
    
    
44. TANG F, Zhu Y, Shen J, Yuan B, et al
    CD44(+) cells enhance pro-tumor stroma in the spatial landscape of colorectal cancer leading edge.
    Br J Cancer. 2025 Mar 12. doi: 10.1038/s41416-025-02968.
    PubMed     Abstract available
    
    
    
45. TAPIAINEN VV, Sirnio P, Elomaa H, Karjalainen H, et al
    Stroma AReactive Invasion Front Areas (SARIFA), tumour immune microenvironment, and survival in colorectal cancer.
    Br J Cancer. 2025 Mar 7. doi: 10.1038/s41416-025-02972.
    PubMed     Abstract available
    
    
    
46. LEE HJ, Park SW, Lee JH, Chang SY, et al
    Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes.
    Br J Cancer. 2025 Mar 3. doi: 10.1038/s41416-025-02964.
    PubMed     Abstract available
    
    
    February 2025
47. ZHANG Y, Wu D, Zhang Z, Ma J, et al
    Correction: Impact of lymph node metastasis on immune microenvironment and prognosis in colorectal cancer liver metastasis: insights from multiomics profiling.
    Br J Cancer. 2025 Feb 17. doi: 10.1038/s41416-025-02941.
    PubMed    
    
    
    
48. BUNDRED J, Lal N, Chan DKH, Buczacki SJA, et al
    Lymph node yield as a surrogate marker for tumour biology and prognosis in colon cancer.
    Br J Cancer. 2025 Feb 14. doi: 10.1038/s41416-025-02949.
    PubMed     Abstract available
    
    
    
49. KATO Y, Seishima R, Hattori K, Kato H, et al
    Significance of homologous recombinant deficiency as a biomarker for drug sensitivity in colorectal cancer.
    Br J Cancer. 2025 Feb 11. doi: 10.1038/s41416-025-02950.
    PubMed     Abstract available
    
    
    January 2025
50. ZHANG Y, Wu D, Zhang Z, Ma J, et al
    Impact of lymph node metastasis on immune microenvironment and prognosis in colorectal cancer liver metastasis: insights from multiomics profiling.
    Br J Cancer. 2025 Jan 3. doi: 10.1038/s41416-024-02921.
    PubMed     Abstract available
    
    
    December 2024
51. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    PubMed     Abstract available
    
    
    November 2024
52. PRETTA A, Ziranu P, Perissinotto E, Ghelardi F, et al
    Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon.
    Br J Cancer. 2024 Nov 27. doi: 10.1038/s41416-024-02902.
    PubMed     Abstract available
    
    
    
53. CHAN WC, Liu L, Bouras E, Zuber V, et al
    Associations of blood lipids and LDL cholesterol lowering drug-targets with colorectal cancer risk: a Mendelian randomisation study.
    Br J Cancer. 2024 Nov 23. doi: 10.1038/s41416-024-02900.
    PubMed     Abstract available
    
    
    
54. POGHOSYAN S, Frenkel N, van den Bent L, Raats D, et al
    VEGF-C propagates 'onward' colorectal cancer metastasis from liver to lung.
    Br J Cancer. 2024 Nov 9. doi: 10.1038/s41416-024-02892.
    PubMed     Abstract available
    
    
    
55. CAMPOS GUDINO R, Neudorf NM, Andromidas D, Lichtensztejn Z, et al
    Loss of EMI1 compromises chromosome stability and is associated with cellular transformation in colonic epithelial cell contexts.
    Br J Cancer. 2024;131:1516-1528.
    PubMed     Abstract available
    
    
    October 2024
56. LI B, Yang W, Liu N, Bi D, et al
    Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study.
    Br J Cancer. 2024 Oct 24. doi: 10.1038/s41416-024-02885.
    PubMed     Abstract available
    
    
    
57. OGAARD N, Jensen SO, Orntoft MW, Demuth C, et al
    Circulating tumour DNA and risk of recurrence in patients with asymptomatic versus symptomatic colorectal cancer.
    Br J Cancer. 2024 Oct 10. doi: 10.1038/s41416-024-02867.
    PubMed     Abstract available
    
    
    
58. NOH H, Lee J, Seyed Khoei N, Peruchet-Noray L, et al
    Serum bilirubin levels and risk of colorectal cancer in Korean adults: results from the Korean Genome and Epidemiology Study-Health Examinee (KoGES-HEXA) Cohort Study.
    Br J Cancer. 2024 Oct 8. doi: 10.1038/s41416-024-02847.
    PubMed     Abstract available
    
    
    
59. SEKHAR H, Kochhar R, Carrington B, Kaye T, et al
    Pre-treatment magnetic resonance imaging in anal cancer: large-scale evaluation of mrT, mrN and novel staging parameters.
    Br J Cancer. 2024;131:1137-1146.
    PubMed     Abstract available
    
    
    September 2024
60. AMODIO V, Vitiello PP, Bardelli A, Germano G, et al
    DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors.
    Br J Cancer. 2024 Sep 13. doi: 10.1038/s41416-024-02848.
    PubMed     Abstract available
    
    
    
61. BOLAND PM, Mukherjee S, Imanirad I, Vijayvergia N, et al
    TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial.
    Br J Cancer. 2024 Sep 7. doi: 10.1038/s41416-024-02845.
    PubMed     Abstract available
    
    
    
62. CHOWDHURY S, Xiu J, Ribeiro JR, Nicolaides T, et al
    Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.
    Br J Cancer. 2024 Sep 4. doi: 10.1038/s41416-024-02826.
    PubMed     Abstract available
    
    
    August 2024
63. GWENZI T, Schrotz-King P, Anker SC, Schottker B, et al
    Prognostic value of post-operative iron biomarkers in colorectal cancer: population-based patient cohort.
    Br J Cancer. 2024 Aug 27. doi: 10.1038/s41416-024-02814.
    PubMed     Abstract available
    
    
    July 2024
64. SEGAL NH, Tie J, Kopetz S, Ducreux M, et al
    COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.
    Br J Cancer. 2024 Jul 25. doi: 10.1038/s41416-024-02796.
    PubMed     Abstract available
    
    
    
65. LAWLER T, Hibler E, Walts ZL, Giurini L, et al
    Associations of diabetes and mortality among colorectal cancer patients from the Southern Community Cohort Study.
    Br J Cancer. 2024 Jul 19. doi: 10.1038/s41416-024-02787.
    PubMed     Abstract available
    
    
    
66. HOU P, Shi P, Jiang T, Yin H, et al
    Correction: DKC1 enhances angiogenesis by promoting HIF-1alpha transcription and facilitates metastasis in colorectal cancer.
    Br J Cancer. 2024 Jul 17. doi: 10.1038/s41416-024-02801.
    PubMed    
    
    
    
67. MASUI H, Kawada K, Itatani Y, Hirai H, et al
    Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment.
    Br J Cancer. 2024;131:63-76.
    PubMed     Abstract available
    
    
    
68. TSUKADA Y, Bando H, Inamori K, Wakabayashi M, et al
    Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
    Br J Cancer. 2024;131:283-289.
    PubMed     Abstract available
    
    
    June 2024
69. YANG L, Yi J, He W, Kong P, et al
    Correction: Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer.
    Br J Cancer. 2024 Jun 26. doi: 10.1038/s41416-024-02768.
    PubMed    
    
    
    
70. EXARCHAKOU A, Rachet B, Lyratzopoulos G, Maringe C, et al
    What can hospital emergency admissions prior to cancer diagnosis tell us about socio-economic inequalities in cancer diagnosis? Evidence from population-based data in England.
    Br J Cancer. 2024;130:1960-1968.
    PubMed     Abstract available
    
    
    May 2024
71. YANG L, Yi J, He W, Kong P, et al
    Death receptors 4/5 mediate tumour sensitivitNot applicably to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer.
    Br J Cancer. 2024 May 25. doi: 10.1038/s41416-024-02673.
    PubMed     Abstract available
    
    
    
72. ZWART K, van Nassau SCMW, van der Baan FH, Koopman M, et al
    Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab.
    Br J Cancer. 2024 May 20. doi: 10.1038/s41416-024-02711.
    PubMed     Abstract available
    
    
    
73. VILLAREAL LB, Falcon DM, Xie L, Xue X, et al
    Hypoxia-inducible factor 3alpha1 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis.
    Br J Cancer. 2024 May 1. doi: 10.1038/s41416-024-02699.
    PubMed     Abstract available
    
    
    
74. QIAO L, Liu Y, Yang Q
    Comment on: "Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial".
    Br J Cancer. 2024;130:1432-1433.
    PubMed    
    
    
    
75. CAI J, Lin K, Luo T, Weng J, et al
    Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial.
    Br J Cancer. 2024;130:1434-1440.
    PubMed     Abstract available
    
    
    
76. MENG XN, Ma JF, Liu YH, Li SQ, et al
    Dynamic genomic changes in methotrexate-resistant human cancer cell lines beyond DHFR amplification suggest potential new targets for preventing drug resistance.
    Br J Cancer. 2024;130:1819-1827.
    PubMed     Abstract available
    
    
    
77. KISAKOL B, Matveeva A, Salvucci M, Kel A, et al
    Identification of unique rectal cancer-specific subtypes.
    Br J Cancer. 2024;130:1809-1818.
    PubMed     Abstract available
    
    
    April 2024
78. REE AH, Saltyte Benth J, Hamre HM, Kersten C, et al
    First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial.
    Br J Cancer. 2024 Apr 25. doi: 10.1038/s41416-024-02696.
    PubMed     Abstract available
    
    
    
79. RIO-VILARINO A, Cenigaonandia-Campillo A, Garcia-Bautista A, Mateos-Gomez PA, et al
    Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
    Br J Cancer. 2024 Apr 4. doi: 10.1038/s41416-024-02667.
    PubMed    
    
    
    
80. BARANYI M, Molnar E, Hegedus L, Gabriel Z, et al
    Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
    Br J Cancer. 2024;130:1059-1072.
    PubMed     Abstract available
    
    
    
81. TIAN Y, Lin Y, Qu C, Arndt V, et al
    Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.
    Br J Cancer. 2024 Apr 1. doi: 10.1038/s41416-024-02638.
    PubMed     Abstract available
    
    
    March 2024
82. FELIU J, Gamez-Pozo A, Martinez-Perez D, Perez-Wert P, et al
    Functional proteomics of colon cancer Consensus Molecular Subtypes.
    Br J Cancer. 2024 Mar 14. doi: 10.1038/s41416-024-02650.
    PubMed     Abstract available
    
    
    
83. ZHANG X, He Y, Li X, Shraim R, et al
    Circulating 25-hydroxyvitamin D and survival outcomes of colorectal cancer: evidence from population-based prospective cohorts and Mendelian randomisation.
    Br J Cancer. 2024 Mar 13. doi: 10.1038/s41416-024-02643.
    PubMed     Abstract available
    
    
    
84. RIO-VILARINO A, Cenigaonandia-Campillo A, Garcia-Bautista A, Mateos-Gomez PA, et al
    Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
    Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02649.
    PubMed     Abstract available
    
    
    
85. DENG LQ, Shi CJ, Zhou ST, Zeng WQ, et al
    EIF4A3-negatively driven circular RNA beta-catenin (circbeta-catenin) promotes colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis.
    Br J Cancer. 2024 Mar 8. doi: 10.1038/s41416-024-02612.
    PubMed     Abstract available
    
    
    
86. GOURIOU C, Lemanski C, Pommier P, Le Malicot K, et al
    Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE.
    Br J Cancer. 2024;130:769-776.
    PubMed     Abstract available
    
    
    February 2024
87. KARAPETIS CS, Liu H, Sorich MJ, Pederson LD, et al
    Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials fro
    Br J Cancer. 2024 Feb 24. doi: 10.1038/s41416-024-02604.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum